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INTRODUCTION 
Orally administered drugs completely absorb only when 
they show fair solubility in gastric medium and such drugs 
shows good bioavailability. Recently more than 40% 
NCEs (new chemical entities) developed in 
Pharmaceutical Industry are practically insoluble in water. 
These poorly water soluble drugs are allied with slow drug 
absorption leading to inadequate and variable 
bioavailability and gastrointestinal mucosal toxicity1. 
The goal of drug delivery system is to achieve blood 
plasma drug concentration. There are different methods 
used for the enhancement of the drug absorption. A drug 
injected intravascular (intravenously and intra- arterially) 
directly enters the systemic circulation and exerts its 
pharmacologic effects. However, most of the drugs are 
administered extravascularly, generally orally. As the oral 
drug delivery is the simplest and easiest way of drug 
administration, because of the greater stability, lesser bulk, 
accurate dosage, cheaper cost of production and easy 
process, solid oral dosage forms have advantages over 
other dosage forms2, 3. 
Therapeutic effectiveness of a drug depends upon the 
bioavailability and ultimately upon the solubility of drug 
molecules. Solubility is one of the important parameter to 
achieve desired concentration of drug in systemic 
circulation for pharmacological response to be shown. 
Currently only 8% of new drug candidates have both high 
solubility and permeability4. 
FACTORS AFFECTING SOLUBILITY 
The solubility depends on the physical form of the solid, 
the nature and composition of solvent medium as well as 
temperature and pressure of system5. 
 Particle size 
The size of the solid particle influences the solubility 
because as a particle becomes smaller, the surface area to 
volume ratio increases. The larger surface area allows a 
greater interaction with the solvent. The effect of particle 
size on solubility can be explained as per the following 
equation6. 
Where, S is the solubility of infinitely large particles, S is 
the solubility of fine particles, V is molar volume, G is the 
surface tension of the solid, R is the radius of the fine 
particle 
 
 Temperature 
Temperature will affect solubility. If the solution process 
absorbs energy then the solubility will be increased as the 
temperature is increased. If the solution process releases 
energy then the solubility will decrease with increasing 
temperature7. Generally, an increase in the temperature of 
the solution increases the solubility of a solid solute. A few 
solid solutes are less soluble in warm solutions. For all 
gases, solubility decreases as the temperature of the 
solution increases8. 
 Pressure 
For gaseous solutes, an increase in pressure increases 
solubility and a decrease in pressure decrease the 
solubility. For solids and liquid solutes, changes in 
pressure have practically no effect on solubility8. 
 Nature of the solute and solvent 
While only 1 gram of lead (II) chloride can be dissolved in 
100 grams of water at room temperature,200 grams of zinc 
chloride can be dissolved.The great difference in the 
solubilities of these two substances is the result of 
differences in their nature8. 
 Molecular size 
The larger the molecule or the higher its molecular weight 
the less soluble the substance. Larger molecules are more 
difficult to surround with solvent molecules in order to 
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solvate the substance. In the case of organic compounds 
the amount of carbon branching will increase the solubility 
since more branching will reduce the size (or volume) of 
the molecule and make it easier to solvate the molecules 
with solvent 9. 
 Polarity 
Generally non-polar solute molecules will dissolve in non-
polar solvents and polar solute molecules will dissolve in 
polar solvents. The polar solute molecules have a positive 
and a negative end to the molecule. If the solvent molecule 
is also polar, then positive ends of solvent molecules will 
attract negative ends of solute molecules. This is a type of 
intermolecular force known as dipole-dipole interaction9. 
 Polymorphs 
A solid has a rigid form and a definite shape. The shape or 
habit of a crystal of a given substance may vary but the 
angles between the faces are always constant. A crystal is 
made up of atoms, ions, or molecules in a regular 
geometric arrangement or lattice constantly repeated in 
three dimensions. This repeating pattern is known as the 
unit cell.The capacity for a substance to crystallize in more 
than one crystalline form is polymorphism10. 
TECHNIQUES OF SOLUBILITY ENHANCEMENT 
There are various techniques available to improve the 
solubility of poorly soluble drugs. Some of the approaches 
to improve the solubility are: -11 
 Physical Modifications 
 Particle size reduction 
Particle size reduction can be achieved by micronisation 
and nanosuspension. Each technique utilizes different 
equipments for reduction of the particle size. 
Micronization- The solubility of drug is often intrinsically 
related to drug particle size. By reducing the particle size, 
the increased surface area improves the dissolution 
properties of the drug. Conventional methods ofparticle 
size reduction, such as comminution and spray drying, rely 
upon mechanical stress to disaggregate the active 
compound. The micronisation is used to increase surface 
area for dissolution12. 
Nanosuspension- Nanosuspensions are sub-micron 
colloidal dispersion of pure particles of drug, which are 
stabilised by surfactants. The advantages offered by 
nanosuspension is increased dissolution rate is due to 
larger surface area exposed, while absence of Ostwald 
ripening is due to the uniform and narrow particle size 
range obtained, which eliminates the concentration 
gradient factor. Techniques for the production of 
nanosuspensions are as follows13. 
1. Homogenization- The suspension is forced under 
pressure through a valve that has nano aperture. This 
causes bubbles of water to form which collapses as 
they come out of valves. This mechanism cracks the 
particles. Three types of homogenizers are commonly 
used such as conventional homogenizers, sonicators, 
and high shear fluid processors14 
2. Wet milling- Active drug in the presence of surfactant 
is defragmented by milling. The nano -
suspensionapproach has been employed for drugs 
including tarazepide, atovaquone, amphotericin B, 
paclitaxel and bupravaquone. All the formulations are 
in the researchstage. One major concern related to 
particle size reduction is the eventual conversion of 
the high-energy polymorph to a low energy crystalline 
form, which may not be therapeutically active one15. 
Drying ofnano suspensions can be done by 
lyophilisation or spray drying 
Other techniques for reduction of the particle size 
includes:- 
Sonocrystallisation 
Recrystallization of poorly soluble materials using liquid 
solvents and antisolvents has also been employed 
successfully to reduce particle size. The novel approach for 
particle size reduction on the basis of crystallisation by 
using ultrasound is sonocrystallisation16. 
Spray drying  
Spray drying is a commonly used method of drying a 
liquid feed through a hot gas. 
Typically, this hot gas is air but sensitive materials such as 
pharmaceuticals and solvents like ethanol require oxygen-
free drying and nitrogen gas is used instead. The liquid 
feed varies depending on the material being dried and is 
not limited to food or pharmaceutical products and may be 
a solution, colloid or a suspension. This process of drying 
is a one step rapid process and eliminates additional 
processing17. Spray drying of the acid dispersed in acacia 
solutions resulted in as much as a50% improvement in 
solubility of poorly water soluble salicylic acid18. 
Modification of the crystal habit 
Polymorphism is the ability of an element or compound to 
crystallize in more then one crystalline form. Different 
polymorphs of drugs are chemically identical, but they 
exhibit different physicochemical properties including 
solubility, melting point, density,texture, stability etc. 
Broadly polymorphs can be classified as enantiotropes and 
monotropes based on thermodynamic properties. 
Drug dispersion in carriers 
The solid dispersion approach to reduce particle size and 
therefore increase the dissolution rate and absorption of 
drugs was first recognised in 196119.The term “solid 
dispersions” refers to the dispersion of one or more active 
ingredients in an inert carrier in a solid state, frequently 
prepared by the melting (fusion) method, solvent method, 
or fusion solvent-method20.Novel additional preparation 
techniques have included rapid precipitation by freeze 
hydrophilic polymers. using methods such as melt 
extrusion21. The most commonly used hydrophilic carriers 
for solid dispersions include polyvinylpyrrolidone22, 
polyethylene glycols23, Plasdone-S63024. Many times 
surfactants may drying  and using supercritical fluids  and 
spray drying , often in the presence of amorphous also 
used in the formation of solid dispersion. Surfactants like 
Tween-80, Docusate sodium, Myrj-52, Pluronic-F68 and 
Sodium Lauryl Sulphate used24. The solubility of 
etoposide25,glyburide26, itraconazole27, 
ampelopsin28,valdecoxib29, celecoxib30, and halofantrine31 
can be improved by solid dispersion using suitable 
hydrophiliccarriers. The eutectic combination 
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ofchloramphenicol/urea32 and sulphathiazole/ urea served 
as examples for the preparation of a poorly soluble drug in 
a highly water soluble carrier. 
Hot melt method 
Sekiguchi and Obi34 used a hot melt method to prepare 
solid dispersion. Sulphathiazole and urea were melted 
together and then cooled in an ice bath. Theresultant solid 
mass was then milled to reduce the particle size. Cooling 
leads to supersaturation, but dueto solidification the 
dispersed drug becomes trapped within the carrier matrix. 
A molecular dispersion can be achieved or not, depends on 
the degree of supersaturation and rate of cooling used in 
the process33. 
Solvent evaporation method 
Tachibana and Nakumara35 were the first to dissolve both 
the drug and the carrier in a common solvent and then 
evaporate the solvent under vacuum to produce a solid 
solution. This enabled them to produce a solid solution of 
the highly lipophilic carotene in the highly water soluble 
carrier polyvinylpyrrolidone. An important prerequisite for 
the manufacture of a solid dispersion using the solvent 
method is that both the drug and the carrier are sufficiently 
soluble in the solvent33. The solvent can be removed by 
various methods like by spray-drying36 or by freeze 
dying37.Temperatures used for solvent evaporation 
generally lie in the range 23-65 0C38. 
Media Milling 
The nanosuspensions are prepared by using high-shear 
media mills. The milling chamber charged with milling 
media, water, drug, and stabilizer is rotated at a very high-
shear rate under controlled temperatures for several days 
(at least 2–7 days). The milling medium is composed of 
glass, Zirconium oxide, or highly cross-linkedpolystyrene 
resin. High energy shear forces are generated as a result of 
the impaction of the milling media with the drug resulting 
into breaking of microparticulate drug to 
nanosizedparticles68. 
Hot-melt extrusion 
Melt extrusion was used as a manufacturing tool in the 
pharmaceutical industry as early as 197139. It has been 
reported that melt extrusion of miscible components results 
in amorphous solid solution formation, whereas extrusion 
of an immiscible component leads to amorphous drug 
dispersed in crystalline excipient40.The process has been 
useful in the preparation of solid dispersions in a single 
step.
 
Table 1: Carriers for solid dispersions
41 
S No. Chemical Class Examples 
1 Acids Citric acid, Tartaric acid 
2 Sugars Dextrose, Sucrose, Sorbitol 
3 Polymeric Polyvinylpyrrolidone, Materials PEG-4000,Cellulose PEG-4000,Cellulose 
4 Surfactants Polyxyethylene Stearate, 
Tweens and Spans 
5 Miscellaneous Urethase ,Urea 
 
Complexation 
Complexation is the association between two or more 
molecules to form a non bonded entity with a well defined 
stichiometry. Complexation relies on relatively weak 
forces such as London forces, hydrogen bonding and 
hydrophobic interactions. There are many types of 
complexing agents and a partial list can be found in below 
table2. 
Staching complexation 
Staching complexes are formed by the overlap of the 
planar regions of aromatic molecules. Nonpolar moieties 
tend to be squeezed out of water by the strong hydrogen 
bonding interactions of water. This causes some molecules 
to minimize the contact with water by aggregation of their 
hydrocarbon moieties. This aggregation is favored by large 
planar non polar regions in the molecule. Stached 
complexes can be homogeneous or mixed. The former is 
known as self association and latter as complexation
45, 46
. 
Some compounds that are known to form staching 
complexes are as Nicotinamide[5456],Anthracene, Pyrene, 
Methylene blue, Benzoic acid, Salicylic acid, Ferulic acid, 
Gentisic acid, Purine, Theobromine, Caffeine, and 
Naphthalene etc. 
Inclusion complexation 
Inclusion complexes are formed by the insertion of the non 
polar molecule or the non polar region of one molecule 
(known as guest) into the cavity of another molecule or 
group of molecules (known as host). The major structural 
requirement for inclusion complexation is a snug fit of the 
guest into the cavity of host molecule. The cavity of host 
must be large enough to accommodate the guest and small 
enough to eliminate water, so that the total contact 
between the water and the nonpolar regions of the host and 
the guest is reduced42, 44. 
Table 2: List of complexing agent
47 
SN.  Types Examples 
1  Inorganic IB- 
2 Coordination Hexaminecobalt(III) chloride 
3 Chelates EDTA, EGTA  
4 Metal Olefin Ferrocene 
5 Inclusion Cyclodextrins, Choleic acid 
6 Molecular 
Complexes 
Polymers 
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Solubilization by surfactants 
Surfactants are molecules with distinct polar and non polar 
regions. Most surfactants consist of a hydrocarbon 
segment connected to a polar group. The polar group can 
be anionic, cationic, zwitter ionic or non ionic48. When 
small polar molecules are added they can accumulate in 
the hydrophobic core of the micelles. This process of 
solubilization is very important in industrial and biological 
processes. The presence of surfactants may lower the 
surface tension and increase the solubility of the drug 
within an organic solvent49. 
Microemulsion 
The term microemulsion was first used by Jack H. 
Shulman in 1959. A microemulsion is a four component 
system composed of external phase, internal phase, 
surfactant and cosurfactant. The addition of surfactant, 
which is predominately soluble in the internal phase unlike 
the co-surfactant, results in the formation of an optically 
clear, isotropic, thermodynamically stable emulsion. It is 
termed as microemulsion because of the internal or 
dispersed phase is < 0.1 μ droplet diameter50. 
Chemical Modifications 
For organic solutes that are ionizable, changing the pH of 
the  system may be simplest and most effective means of 
increasing aqueous solubility. Under the proper conditions, 
the solubility of an ionizable drug can increase 
exponentially by adjusting the pH of the solution. A drug 
that can be efficiently solubilized by pH control should be 
either weak acid with a low pKa or a weak base with a 
high pKa. Similar to the lack of effect of heat on the 
solubility of non-polar substances, there is little effect of 
pH on non ionizable substances51. 
Co-crystallisation 
The new approach available for the enhancement of drug 
solubility is through the application of the co-crystals, it is 
also referred as molecular complexes. If the solvent is an 
integral part of the network structure and forms at least 
two component crystals, then it may be termed as co-
crystal. If the solvent does not participate directly in the 
network itself, as in open framework structures, then it is 
termed as clathrate (inclusion complex). A co-crystal may 
be defined as a crystalline material that consists of two or 
more molecular (and electrically neutral) species held 
together by non-covalent forces. Co-crystals are more 
stable, particularly as the co-crystallizing agents are solids 
at room temperature52. 
Co-solvency 
The solubilisation of drugs in co-solvents is a technique for 
improving the solubility of poorly soluble drug53. It is 
well-known that the addition of an organic co solvent to 
water can dramatically change the solubility of drugs. 
Most co solvents have hydrogen bond donor and/or 
acceptor groups as well as small hydrocarbon regions. 
Their hydrophilic hydrogen bonding groups ensure water 
miscibility, while their hydrophobic hydrocarbon regions 
interfere with waters hydrogen bonding network, reducing 
the overall intermolecular attraction of water. By 
disrupting waters self-association, co solvents reduce 
waters ability to squeeze out non-polar, hydrophobic 
compounds, thus increasing solubility. A different 
perspective is that by simply making the polar water 
environment more non polar like the solute, cosolvents 
facilitate solubilization. Solubility enhancement as high as 
500-fold is achieved using 20% 2-pyrrolidone54. 
Molecular encapsulation with cyclodextrins 
The beta- and gamma- cyclodextrins and several of their 
derivatives are unique in having the ability to form 
molecular inclusion complexes with hydrophobic drugs 
having poor aqueous solubility. These bucket shaped 
oligosaccharides produced from starch are versatile in 
having a hydrophobic cavity of size suitable enough to 
accommodate the lipophilic drug as guests; the outside of 
the host molecule is relatively hydrophilic. Thus the 
molecularly encapsulated drug has greatly improved 
aqueous solubility and dissolution rate. There are several 
examples of drugs with improved bioavailability due to 
such phenomenon- thiazide diuretics, barbiturates and a 
number of NSAIDs55. 
Solubilizing agents 
The solubility of poorly soluble drug can also be improved 
by various solubilizing materials. PEG 400 is improving 
the solubility of hydrochlorthiazide56. Modified gum 
karaya (MGK), a recently developed excipient was 
evaluated as carrier for dissolution enhancement of poorly 
soluble drug, nimodipine .The aqueous solubility of the 
antimalarial agent halofantrine is increased by addition of 
caffeine and nicotinamide57. 
Nanotechnology approaches 
Nanotechnology will be used to improve drugs that 
currently have poor solubility. Nanotechnology refers 
broadly to the study and use of materials and structures at 
the nanoscale level of approximately 100 nanometers (nm) 
or less. For many new chemical entities of very low 
solubility, oral bioavailability enhancement by 
micronisation is not sufficient because micronized product 
has the tendency of agglomeration, whichleads to 
decreased effective surface area for dissolution and the 
next step taken was Nanonisation58. 
Nanocrystal 
A nanocrystal is a crystalline material with dimensions 
measured in nanometers; a nano particle with structure that 
is mostly crystalline. The nano-crystallization is defined as 
a way of diminishing drug particles to the size range of 1-
1000 nanometers. Nano-crystallization is thought to be an 
universal method that can be applied to any drug59. There 
are two distinct methods used for producing nanocrystals; 
’bottom-up’ and ’top-down’ development60. The top-down 
methods (i.e. Milling and High pressure homogenization) 
start milling down from macroscopic level, e.g. from a 
powder that is micron sized. In bottom-up methods (i.e. 
Precipitation and Cryo-vacuum method), nano scale 
materials are chemically composed from atomic and 
molecular components. 
Milling 
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Nano scale particles can be produced by wet-milling 
process61. In ball mills, particle size reduction is achieved 
by using both impact and attrition forces. The most 
common models are a tumbling ball mill and a stirred 
media mill. One problem of this method is the degradation 
of mill surfaces and subsequent suspension contamination. 
High pressure homogenization 
In high pressure homogenization, an aqueous dispersion of 
the crystalline drug particles is passed with high pressure 
through a narrow homogenization gap with a very high 
velocity62. Homogenisation can be performed in water 
(Disso Cubes) or alternatively innon-aqueous media or 
water-reduced media (Nanopure) . The particles are 
disintegrated by cavitation and shear forces. The static 
pressure exerted on the liquid causes the liquid to boil 
forming gas bubbles63. The particle size obtained during 
the homogenization process depends primarily on the 
nature of the drug, the pressure applied and the number of 
homogenization cycles. 
Precipitation 
In the precipitation method a dilute solution is first 
produced by dissolving the substance in a solvent where its 
dissolution is good64.The solution with the drug is then 
injected into water, which acts as a bad solvent. At the 
time of injection, the water has to be stirred efficiently so 
that the substance will precipitate as nano-crystals. Nano-
crystals can be removed from the solution by filtering and 
then dried in air. 
NanoMorph 
The Nano Morph technology is to convert drug substances 
with low water-solubility from a coarse crystalline state 
into amorphous nano particles. A suspension of drug 
substance in solvent is fed into a chamber, where it is 
rapidly mixed with another solvent. Immediately the drug 
substance suspension is converted into a true molecular 
solution. The admixture of an aqueous solution of a 
polymer induces precipitation of the drug substance. The 
polymer keeps the drug substance particles in their 
nanoparticulatestate and prevents them from aggregation 
or growth. Water redispersable dry powders can be 
obtained from the nanosized dispersion by conventional 
methods, e.g. nspray-drying. Nanotechnology approaches 
to improve the solubility of hydrophobic drugs shown in 
table.
 
Table 4: Nanotechnology approaches to improve the solubility of hydrophobic drugs
65, 66
 
Company  Nanoparticulate 
Technologies 
Description 
 
Elan Nano Crystal Nano crystal drug particles (<1000 nm) produced by wetmilling and stabilised 
against agglomeration via surface adsorption of stabilizers applied to NMEs eg. 
Reformulation of existing drugs eg. Sirolimus 
BioSante CAP Calcium-phosphate based nanoparticles: for improved oral bioavailability of 
hormones/proteins such as insulin 
 
Hydrotropy 
Hydrotropy is a solubilization phenomenon whereby 
addition of large amount of a second solute results in an 
increase in the aqueous solubility of another solute. 
Concentrated aqueous hydrotropic solutions of sodium 
benzoate, sodium salicylate, urea, nicotinamide, sodium 
citrate and sodium acetate have been observed to enhance 
the aqueous solubilities of many poorly water soluble 
drugs67. 
Micellar solubilization 
The use of surfactants to improve the dissolution 
performance of poorly soluble drug products is probably 
the basic, primary, and the oldest method. Surfactants 
reduce surface tension and improve the dissolution of 
lipophilic drugs in aqueous medium. They are also used to 
stabilise drug suspensions.When the concentration of 
surfactants exceeds their critical micelle concentration 
(CMC, which is in the range of 0.05–0.10% formost 
surfactants),micelle formation occurs which entrap the 
drugs within the micelles. This is known as micellization 
and generally results in enhanced solubility of poorly 
soluble drugs. Surfactant also improves wetting of solids 
and increases the rate of disintegration of solid into finer 
particles 69. Commonly used non-ionic surfactants include 
polysorbates, polyoxyethylated castor oil, 
polyoxyethylated glycerides, lauroyl macroglycerides, and 
mono- and di-fatty acid esters of low molecular weight 
polyethylene glycols. Surfactants are also often used to 
stabilize microemulsions and suspensions into which drugs 
are dissolved70, 71. 
Examples of poorly soluble compounds that useMicellar 
solubilization are antidiabetic drugs, gliclazide, 
glyburide,glimepiride, glipizide, repaglinide, pioglitazone, 
and rosiglitazone
72
. 
Supercritical fluid (scf) process 
Another novel nanosizing and solubilisation technology 
whose application has increased in recent years is particle 
size reduction via supercritical fluid (SCF) processes. 
Supercritical fluids are fluids whose temperature and 
pressur eare greater than its critical temperature (Tc) and 
critical pressure (Tp), allowing it to assume the properties 
of both a liquid and a gas. At near-critical temperatures, 
SCFs, are highly compressible allowing moderate changes 
in pressure to greatly alter the density and mass transport 
characteristics of the fluid that largely determine its 
solvent power. Once the drug particles are solubilised 
within the SCF (usually carbon dioxide), theymay be 
recrystallised at greatly reduced particle sizes. The 
flexibility and precision offered by SCF processes allows 
micronisation of drug particles within narrow ranges of 
particle size, often to submicron levels. Current SCF 
processes have demonstrated the ability to create 
nanoparticulate suspensions of particles 5–2,000nm in 
diameter. Several pharmaceutical companies, such as 
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Nektar Therapeutics and Lavipharm, are specializing in 
particle engineering via SCF technologies for particle size 
reduction and solubility enhancement. Several methods of 
SCF processing have been developed to address individual 
aspects of these shortcomings, such as precipitation with 
compressed antisolvent process (PCA), solution enhanced 
dispersion by SCF (SEDS), supercritical antisolvent 
processes (SAS), rapid expansion of supercritical solutions 
(RESS), gas anti solvent recrystallization (GAS), and 
aerosol supercritical extraction system (ASES)73. 
CONCLUSION 
Dissolution of drug is the rate determining step for oral 
absorption of the poorly water soluble drugs and solubility 
is the basic requirement for the absorption of the drug from 
GIT. The various techniques described above alone or in 
combination can be used to enhance the solubility of the 
drugs. Proper selection of solubility enhancement method 
is the key to ensure the goals of a good formulation like 
good oral bioavailability, reduce frequency of dosing and 
better patient compliance combined with a low cost of 
production. Selection of method for solubility 
enhancement depends upon drug characteristics like 
solubility, chemical nature, melting point, absorption site, 
physical nature, pharmacokinetic behavior and so forth, 
dosage form requirement like tablet or capsule 
formulation, strength, immediate, or modified release and 
so forth, and regulatory requirements like maximum daily 
dose of any excipients and/or drug, approved excipients, 
analytical accuracy and so forth.
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